European Pharmaceutical Review

JULY 2, 2025

Sandoz has begun construction of a new biosimilars production facility in Brnik, Slovenia. billion before the end of the decade, by 2029. The new high-tech facility will produce both existing and upcoming biosimilar medicines in Sandoz’s portfolio. “… With a commitment of over $1.1 “… With a commitment of over $1.1

Biosimilars 52

Biosimilars Packaging 52

Pharmaceutical Technology

JULY 15, 2022

In a budget change proposed in February and confirmed in May , California’s Department of Health Care Access and Information (HCAI) requested a one-time investment of $100 million for Newsom’s CalRx Biosimilar Insulin initiative. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin.

Biosimilars 131

Biosimilars Diabetes Documentation Packaging 131

Pharmaceutical Technology

JULY 1, 2025

Experts praise the reforms to rare disease and antimicrobial research, but they worry that some provisions in the EU Pharma Package may harm innovation on the continent, contrary to its stated objectives. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence.

Packaging 52

Packaging Drug Development Chemotherapy Biosimilars 52

Pharmaceutical Technology

JULY 4, 2025

Biosimilars and generics flood the market upon patent loss, which exerts pricing pressure on the branded product. There has been a push by the Trump administration to increase biosimilar and generic drug use in the US. Biosimilars and generics can be as much as 80% cheaper than branded alternatives.

Biosimilars 52

Biosimilars Chemotherapy Packaging Communication 52